CAS 1151516-14-1

Acetic acid, 2-[[5-bromo-4-(4-cyclopropyl-1-naphthalenyl)-4H-1,2,4-triazol-3-yl]thio]-, sodium salt (1:1)

CAS : 1151516-14-1

Formule : C₁₇H₁₃BrN₃NaO₂S

Degré de pureté : 98%

Couleur et forme : Solid

Masse moléculaire : 426.2628

Ref: IN-DA000GBQ

Lesinurad Sodium

CAS : 1151516-14-1

Lesinurad Sodium

Degré de pureté : 98%

Masse moléculaire : 426.26g/mol

Ref: 54-OR1027806

Lesinurad sodium

CAS : 1151516-14-1

Lesinurad sodium

Degré de pureté : ≥98%

Masse moléculaire : 426.26g/mol

Ref: 54-BUP01878

Lesinurad sodium

CAS : 1151516-14-1

Lesinurad sodium (RDEA594 sodium) is a selective inhibitor of uric acid reabsorption and is used in the study of cardiovascular diseases.

Formule : C₁₇H₁₃BrN₃NaO₂S

Degré de pureté : 99.97%

Couleur et forme : Solid

Masse moléculaire : 426.26

Ref: TM-T21301

Lesinurad sodium

CAS : 1151516-14-1

Lesinurad sodium is a prodrug that is hydrolyzed to form ethyl formate, which inhibits the acid transporter (NT) in the kidneys. It is used for the treatment of chronic gouty arthritis and hyperuricemia associated with the use of xanthine oxidase inhibitors or allopurinol. Lesinurad sodium has been shown to be effective in reducing serum uric acid levels and pain symptoms in patients with chronic gouty arthritis. The drug has a plasma concentration-time curve that follows first-order kinetics and an elimination half-life of 15 hours. Lesinurad sodium has been shown to inhibit NT activity by structural formula, reaction yield, introducing techniques, and pharmacodynamics.

Formule : C₁₇H₁₃BrN₃O₂S·Na

Degré de pureté : Min. 95%

Masse moléculaire : 426.27 g/mol

Ref: 3D-BWB51614